Načítá se...
Raltitrexed Inhibits HepG2 Cell Proliferation via G(0)/G(1) Cell Cycle Arrest
Raltitrexed (RTX) is an antimetabolite drug used as a chemotherapeutic agent for treating colorectal cancer, malignant mesothelioma, and gastric cancer. The antitumor capacity of RTX is attributed to its inhibitory activity on thymidylate synthase (TS), a key enzyme in the synthesis of DNA precursor...
Uloženo v:
| Vydáno v: | Oncol Res |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Cognizant Communication Corporation
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7838684/ https://ncbi.nlm.nih.gov/pubmed/27098147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504016X14562725373671 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|